Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action-Reference-Cited by-同舟云学术

Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action

Published:2017-06-27 Issue:15 Volume:1 Page:1206-1214
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Keshava Shiva¹,Sundaram Jagan¹,Rajulapati Anuradha¹,Esmon Charles T.²,Pendurthi Usha R.¹,Rao L. Vijaya Mohan¹^ORCID

Affiliation:

1. Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and

2. Coagulation Biology Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, OK

Abstract

Key PointsEPCR levels influence the hemostatic effect of rFVIIa in hemophilia therapy. FVIIa binding to EPCR influences the hemostatic effect of FVIIa because of downregulation of protein C anticoagulation pathway.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/15/1206/878706/advances004143.pdf

Reference37 articles.

1. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium;Ghosh;J Biol Chem,2007

2. Multifunctional specificity of the protein C/activated protein C Gla domain;Preston;J Biol Chem,2006

3. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity;López-Sagaseta;J Thromb Haemost,2007

4. The tissue factor pathway: how it has become a “prima ballerina.”;Rapaport;Thromb Haemost,1995

5. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor;Mohan Rao;Blood,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coagulation protease–induced extracellular vesicles: their potential effects on coagulation and inflammation;Journal of Thrombosis and Haemostasis;2024-08

2. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro;Thrombosis Research;2024-05

3. Endothelial Protein C Receptor and Its Impact on Rheumatic Disease;Journal of Clinical Medicine;2024-03-31

4. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective;Haemophilia;2024-02-05

5. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors;Expert Review of Hematology;2023-09-25